|
業務類別
|
Biotechnology |
|
業務概覽
|
Oruka Therapeutics Inc a clinical-stage biopharmaceutical company focused on developing novel monoclonal antibody therapeutics for psoriasis (PsO) and other inflammatory and immunology (I&I) indications. Its programs are to treat and potentially modify disease by targeting mechanisms with efficacy and safety involved in disease pathology and the activity of pathogenic tissue-resident memory T cells (TRMs). Its program, ORKA-001, is designed to target the p19 subunit of interleukin-23 (IL-23p19) for the treatment of PsO. Its co-lead program, ORKA-002, is designed to target interleukin-17A and interleukin-17F (IL-17A/F) for the treatment of PsO, hidradenitis suppurativa (HS), psoriatic arthritis (PsA), and otherconditions. |
| 公司地址
| 855 Oak Grove Avenue, Suite 100, Menlo Park, CA, USA, 94025 |
| 電話號碼
| +1 650 606-7910 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.orukatx.com |
| 員工數量
| 68 |
| Mr. Paul T. Quinlan PhD |
General Counsel and Corporate Secretary |
美元 474.00K |
17/04/2026 |
| Dr. Lawrence Otto Klein, PhD |
Director, President and Chief Executive Officer |
美元 624.00K |
17/04/2026 |
| Mr. Arjun Agarwal |
Senior Vice President, Finance, Treasurer and Principal Accounting Officer |
-- |
17/04/2026 |
| Ms. Laura Lee Sandler |
Chief Operating Officer |
-- |
17/04/2026 |
| Dr. Joana Goncalves, M.D. |
Chief Medical Officer |
美元 474.00K |
17/04/2026 |
|
|
| Mr. Christopher Martin |
Independent Director |
17/04/2026 |
| Dr. Lawrence Otto Klein, PhD |
Director, President and Chief Executive Officer |
17/04/2026 |
| Dr. Samarth Kulkarni, PhD |
Chairman of the Board |
17/04/2026 |
| Mr. Peter Harwin |
Independent Director |
17/04/2026 |
| Dr. Carl Dambkowski, M.D. |
Independent Director |
17/04/2026 |
| Ms. Kristine M. Ball |
Independent Director |
17/04/2026 |
|
|
|
|
